| Literature DB >> 18974882 |
Edwin Lasonder1, Chris J Janse, Geert-Jan van Gemert, Gunnar R Mair, Adriaan M W Vermunt, Bruno G Douradinha, Vera van Noort, Martijn A Huynen, Adrian J F Luty, Hans Kroeze, Shahid M Khan, Robert W Sauerwein, Andrew P Waters, Matthias Mann, Hendrik G Stunnenberg.
Abstract
Plasmodium falciparum sporozoites that develop and mature inside an Anopheles mosquito initiate a malaria infection in humans. Here we report the first proteomic comparison of different parasite stages from the mosquito -- early and late oocysts containing midgut sporozoites, and the mature, infectious salivary gland sporozoites. Despite the morphological similarity between midgut and salivary gland sporozoites, their proteomes are markedly different, in agreement with their increase in hepatocyte infectivity. The different sporozoite proteomes contain a large number of stage specific proteins whose annotation suggest an involvement in sporozoite maturation, motility, infection of the human host and associated metabolic adjustments. Analyses of proteins identified in the P. falciparum sporozoite proteomes by orthologous gene disruption in the rodent malaria parasite, P. berghei, revealed three previously uncharacterized Plasmodium proteins that appear to be essential for sporozoite development at distinct points of maturation in the mosquito. This study sheds light on the development and maturation of the malaria parasite in an Anopheles mosquito and also identifies proteins that may be essential for sporozoite infectivity to humans.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18974882 PMCID: PMC2570797 DOI: 10.1371/journal.ppat.1000195
Source DB: PubMed Journal: PLoS Pathog ISSN: 1553-7366 Impact factor: 6.823
Figure 1Distribution of identified P. falciparum proteins over different life-cycle stages.
(A) Venn diagram depicting the distribution of detected P. falciparum proteins over three different mosquito life-cycle stages (oocysts, oocyst-derived sporozoites and salivary gland sporozoites). Numbers represent the number of proteins, that are either shared between 2 or 3 stages (overlapping areas) or that are detected in a single stage. (B) Comparison of the expression of P. falciparum proteins detected in the three mosquito stage proteomes to the blood stage proteomes described previously [15]. (C) The percentage of proteins exclusively detected in only one proteome out of 6 different life cycle stage proteomes, i.e. ASX - asexual blood stages; GCT – gametocytes; GAM – gametes; OOC – oocysts; ODS - oocyst-derived sporozoites; SGS - salivary gland sporozoites.
Figure 2Gene Ontology term enrichment analysis of mosquito stage proteome.
(A) Enrichment for GO ‘Biological Process’ terms of proteins detected in mosquito and blood stages. The figure shows terms on the x-axis that are significantly enriched (p<0.004) by more than four fold. GO terms of the shared set of proteins (n = 478, purple bars) is compared to terms of all predicted P. falciparum proteins (5410, green bars). The y-axis displays the fraction relative to all GO Biological Process terms. (B) Enrichment for GO ‘Molecular Function’ main terms of proteins detected specifically in mosquito stages (and blood stages). GO terms of the mosquito specific set of proteins (n = 250, blue bars) is compared terms of all predicted P. falciparum proteins (5410, green bars). The y-axis displays the fraction relative to all GO Molecular Function terms. These terms do not show a significant enrichment (p>0.5).
Characterized proteins involved in sporozoite development and invasion of host cells.
| Accession nr | protein name (1) | protein involved in (2) | nr unique pept/protein in life cycle stages (3) | Reference | |||||
| ASX | GCT | GAM | OOC | ODS | SGS | ||||
| PF14_0067 | CCp3 | sporozoite development | - | 31 | 10 | - | - | - | Claudianos |
| PF14_0532 | CCp2 | sporozoite development | - | 39 | 20 | - | - | - | Pradel |
| PFC0180c | IMC1 | sporozoite development (cell shape) | - | - | - | 0 | 9 | 25 | Khater |
| PFC0210c | CS | sporozoite development, salivary gland and hepatocyte invasion | - | - | - | 2 | 5 | 9 | Menard |
| PFB0325c | cysteine protease | egress from oocyst | - | - | - | - | 16 | 23 | Aly |
| PF13_0233 | myosin A | sporozoite gliding motility | - | - | - | 2 | 39 | 49 | Bergman |
| PFL2225w | MTIP | sporozoite gliding motility | 1 | 1 | - | 2 | 4 | 3 | Bergman |
| PF13_0201 | SSP2/TRAP | sporozoite gliding motility, salivary gland and hepatocyte invasion | - | - | - | 1 | 6 | 35 | Rogers |
| PFI0550w | CRMP1 | salivary gland invasion | - | 1 | - | - | - | - | Thompson |
| MAL7P1.92 | CRMP2 | salivary gland invasion | - | - | - | - | - | - | Thompson |
| PF11_0486 | MAEBL | salivary gland invasion | - | - | - | - | 33 | 1 | Kariu |
| MAL13P1.212 | SPECT1 | cell traversal hepatocytes | 1 | - | - | - | - | 16 | Ishino |
| PFD0430c | SPECT2 | cell traversal hepatocytes | 1 | - | - | - | - | 26 | Ishino |
| PFL0800c | CelTOS | cell traversal hepatocytes | - | - | - | - | - | 6 | Kariu |
| PFF1420w | PL | cell traversal hepatocytes | - | - | - | - | - | - | Bhanot |
| PF11_0344 | AMA-1 | hepatocyte invasion | 1 | - | - | - | 2 | 19 | Silvie |
| PFB0570w | SPATR | hepatocyte invasion | - | - | - | - | - | 5 | Chattopadhyay |
| PFB0095c | PfEMP3 | hepatocyte invasion | 3 | - | - | - | - | - | Grüner |
| PF07_0006 | STARP | hepatocyte invasion | - | - | - | - | - | - | Pasquetto |
| GI:1477963 | SALSA | hepatocyte invasion | - | - | - | - | - | - | Puentes |
| PFA0200w | TRSP | hepatocyte invasion | - | - | - | - | 1 | 3 | Labaeid |
| PFD0215c | pf52 protein/P36p | hepatocyte invasion - development | - | - | - | - | - | 5 | Ishino |
| PFD0210c | pbs36 homologue/P36 | hepatocyte invasion - development | - | - | - | - | - | 8 | Ishino |
CCP (members of the LCCL protein family), IMC (inner membrane complex), CS (circumsporozoite), MTIP (myosin A tail domain interacting protein), SSP2 (sporozoite surface protein), TRAP (Thrombospondin related anonymous protein), CRMP (cysteine repeat modular protein), MAEBL (membrane antigen erythrocyte binding like protein ), SPECT (sporozoite microneme protein essential for cell traversal ), CelTOS (cell-traversal protein for ookinetes and sporozoites), PL (phosphoplipase), AMA (apical membrane antigen), SPATR (secreted protein with altered thrombospondin domain), EMP (erythrocyte membrane protein), STARP (sporozoite threonine and asparagine-rich protein), SALSA (sporozoite and liver stage antigen); TRSP (thrombospondin related protein).
The role of these proteins has been determined by functional analysis in gene-knockout and/or antibody-inhibition studies.
ASX - asexual blood stages; GCT – gametocytes; GAM – gametes; OOC – oocysts; ODS - oocyst-derived sporozoites; SGS - salivary gland sporozoites.
Expression of Plasmodium proteins containing thrombospondin type 1 (TSP1) and/or von Willebrand factor A (vWA) domains in different life cycle stage proteomes.
| Accession nr | Protein name | domain | nr unique pept/prot in life cycle stages (1) | Reference | ||||||
| 1 | 2 | ASX | GCT | GAM | OOC | ODS | SGS | |||
| PF13_0201 | TRAP | TSP1 | VWA | - | - | - |
|
|
| Rogers |
| PFC0210c | CS | TSP1 | - | - | - |
|
|
| Menard | |
| PFA0200w | TRSP | TSP1 | - | - | - | - |
|
| Kaiser | |
| MAL8P1.45 | hypothetical protein | TSP1 | - | - | - | - |
| - | Aravind | |
| PFB0570w | SPATR | TSP1 |
| Chattopadhyay | ||||||
| PFF0800w | TRAP-like protein | TSP1 | VWA | - |
| - | - | - |
| Moreira |
| PFL0870w | PTRAMP | TSP1 | - | - | - | - | - |
| Thompson | |
| PF10_0281 | MTRAP | TSP1 | - | - | - | - | - | - | Baker | |
| PF08_0136b | WARP | TSP1 | - | - | - | - | - | - | Yuda | |
| PFC0640w | CTRP | TSP1 | VWA |
|
| - | - | - | - | Baker |
| PFL0875w | hypothetical protein | TSP1 | - | - | - | - | - | - | Aravind | |
ASX - asexual blood stages; GCT – gametocytes; GAM – gametes; OOC – oocysts; ODS - oocyst-derived sporozoites; SGS - salivary gland sporozoites.
Characteristics of mosquito stage specific proteins selected on the basis of expression pattern during sporozoite development.
| Accession nr (1) | Protein Name | MW (kDa) | Group (2) | MOTIF PREDICTION (3) | ORTHOLOGY PREDICTION (4) | nr unique peptide/protein (5) | ||||||||||
| SP | GPI | nr TM (mean) | PEXEL | SMART domain | Ortho MCL group | nr species | additional nr species | OOC | ODS | SGS | Mosq. fr. | |||||
| Plasm. | Api | other | ||||||||||||||
|
|
| 710 | I | 5.3 | OG2_80072 | 6 | 1 | 0 | 1 | 32 | 0.97 | |||||
| PF11_0486 | MAEBL | 243 | I | 1 | 1.3 | OG2_70757 | 6 | 3 | >10 | 33 | 1 | 1 | ||||
| MAL13P1.66 | hypothetical protein | 346 | I | 1.8 | OG2_93592 | 6 | 0 | 0 | 26 | 1 | 0.93 | |||||
| PFF0645c | integral membrane protein | 163 | I | 6.5 | DUF1222 | OG2_76677 | 6 | 3 | 9 | 18 | 1 | 0.95 | ||||
| PF14_0404 | hypothetical protein | 408 | I | 0.8 | OG2_71079 | 6 | 1 | >10 | 20 | 0.91 | ||||||
| PF14_0722 | CRMP4 | 699 | I | 1 | 9.0 | 3 * GCC2_GCC3 | OG2_81006 | 5 | 0 | 0 | 16 | 0.94 | ||||
|
|
| 144 | I | 1 | 6.8 | OG2_89567 | 5 | 0 | 0 | 13 | 1 | |||||
| PF13_0338 | hypothetical protein (Pf92) | 93 | I | 1 | 1 | 1.0 | s48-s45 | OG2_117922 | 3 | 0 | 0 | 11 | 1 | |||
| MAL8P1.126 | serine protease | 101 | I | 1 | 1.5 | 1 | Trypsin | OG2_77036 | 3 | 3 | >10 | 11 | 1 | |||
|
|
| 127 | I | 1 | 4.8 | 1 | OG2_79434 | 6 | 5 | 0 | 9 | 1 | ||||
| MAL8P1.135 | hypothetical protein | 116 | I | 8.8 | OG2_74819 | 6 | 2 | >10 | 8 | 1 | ||||||
| PF14_0694 | protein disulfide isomerase | 66 | I | 1 | 0.8 | Thioredoxin | OG2_78996 | 6 | 5 | 3 | 8 | 1 | ||||
| PF11_0229 | hypothetical protein | 57 | I | 1 | 1 | 0.8 | OG2_93024 | 6 | 0 | 0 | 7 | 1 | ||||
| PFE0340c | hypothetical protein | 87 | I | 5.0 | Rhomboid | OG2_70960 | 6 | 5 | >10 | 6 | 1 | |||||
| MAL13P1.119 | cAMP-specific 3′,5′-cyclic | 86 | I | 4.5 | HDc | OG2_93460 | 6 | 0 | 0 | 6 | 1 | |||||
| phosphodiesterase 4B | ||||||||||||||||
| PFD0295c | hypothetical protein | 85 | I | 1 | 1.0 | CCP | OG2_89419 | 6 | 1 | 0 | 5 | 1 | ||||
| PF11_0064 | hypothetical protein | 85 | I | 1 | 1.5 | OG2_92898 | 6 | 0 | 0 | 4 | 1 | |||||
| PF11_0141 | UDP-galactose transporter | 39 | I | 8.0 | UAA; TPT; DUF6 | OG2_72118 | 6 | 4 | >10 | 3 | 1 | |||||
| PF10_0223 | hypothetical protein | 49 | I | 4.3 | OG2_92751 | 6 | 0 | 0 | 3 | 1 | ||||||
| PF11_0344 | AMA-1 | 72 | II | 1 | 1.5 | AMA-1 | OG2_81783 | 6 | 3 | no | 2 | 19 | 0.95 | |||
| PFD0430c | SPECT2 (PLP1) | 94 | II | 1 | 1.5 | MACPF | OG2_81960 | 6 | 3 | 2 | 26 | 0.96 | ||||
|
|
| 47 | II | 0.5 | OG2_84483 | 6 | 1 | 1 | 20 | 1 | ||||||
| MAL13P1.212 | SPECT1 | 28 | II | 1 | 0.5 | OG2_105334 | 4 | 0 | 0 | 16 | 0.94 | |||||
| PFL0800c | CelTOS | 20 | II | 1 | 0.5 | OG2_92921 | 5 | 0 | 0 | 6 | 1 | |||||
| PFB0570w | SPATR | 29 | II | 1 | 0.8 | TSP1 | OG2_89620 | 6 | 1 | 0 | 5 | 1 | ||||
|
|
| 75 | II | 1 | 1 | 1.3 | OG2_89698 | 6 | 0 | 1 | 4 | 1 | ||||
| PFE0395c | hypothetical protein (Pf38) | 41 | II | 1 | 1 | 1.3 | s48_45 | OG2_93113 | 6 | 0 | 0 | 3 | 1 | |||
| PFC0905c | hypothetical protein | 360 | III | 1 | 1.0 | OG2_86694 | 6 | 0 | 0 | 78 | 133 | 27 | 0.99 | |||
| PF13_0233 | myosin a | 92 | III | 0.8 | Myosin_head | OG2_70807 | 6 | 5 | >10 | 2 | 39 | 49 | 1 | |||
|
|
| 113 | III | 1 | 1.8 | OG2_86498 | 6 | 2 | 0 | 3 | 42 | 38 | 1 | |||
| PF13_0201 | TRAP | 65 | III | 1 | 1.8 | VWA; TSP1 | OG2_79098 | 6 | 3 | 5 | 1 | 6 | 35 | 1 | ||
| PFC0210c | CS | 43 | III | 1 | 1 | 1.0 | 1 | TSP1 | OG2_87352 | 1 | 2 | 4 | 2 | 5 | 9 | 1 |
| PFB0325c | cysteine protease | 78 | III | 0.5 | Pept_C1 | OG2_93012 | 6 | 0 | 0 | 16 | 23 | 1 | ||||
| PFC0180c | membrane skeletal protein | 98 | III | 0.8 | OG2_89543 | 6 | 1 | 0 | 9 | 25 | 1 | |||||
| MAL8P1.73 | hypothetical protein | 141 | III | 3.3 | OG2_84418 | 6 | 2 | 0 | 16 | 13 | 1 | |||||
|
|
| 93 | III | 4.0 | OG2_92998 | 6 | 0 | 0 | 7 | 22 | 0.97 | |||||
| PF13_0234 | phosphoenol pyruvate carboxykinase | 66 | III | 1.0 | PEPCK_ATP | OG2_72511 | 6 | 3 | >10 | 8 | 17 | 0.93 | ||||
| PF08_0008 | hypothetical protein | 85 | III | 1 | 1 | 2.0 | OG2_89440 | 6 | 1 | 0 | 3 | 22 | 0.93 | |||
| PFL1165w | hypothetical protein | 96 | III | 0.8 | 1 | OG2_93001 | 6 | 0 | 0 | 15 | 6 | 1 | ||||
| MAL13P1.254 | hypothetical protein | 31 | III | 1 | 2.0 | OG2_92954 | 6 | 0 | 0 | 11 | 9 | 1 | ||||
| PF14_0495 | hypothetical protein | 249 | III | 1 | 2.0 | OG2_78524 | 6 | 3 | 5 | 12 | 6 | 1 | ||||
| PF14_0286 | glutamate dehydrogenase | 57 | III | 1 | 1 | 0.5 | ELFV_dehydrog N, ELFV_dehydrog | OG2_70937 | 6 | 1 | >10 | 3 | 12 | 1 | ||
|
|
| 26 | III | 1 | 1.3 | 1 | OG2_72432 | 5 | 3 | >10 | 5 | 4 | 1 | |||
Genes shown in bold been further characterized by functional analysis through targeted gene disruption (see Table 4).
Classification of proteins based on their protein expression patterns: group I (ODS-enriched), group II (SGS-enriched), and group III (ODS/SGS-enriched).
Abbreviations used for motif predictions: are Signal Peptide (SP), Glycosylphosphatidylinisotol anchored proteins (GPI), Trans Membrane regions (average of number of TM regions predicted by four algorithms) and N-terminal PEXEL (Plasmodium export element within first 200 amino acids obtained from http://www.plasmodb.org). Abbreviations for predicted SMART domains: Apical membrane antigen (AMA), Complement control proteins (CCP), Domain of Unknown Function (DUF), Glu/Leu/Phe/Val dehydrogenase dimerisation domain (ELFV_dehydrog_N), Glutamate/Leucine/Phenylalanine /Valine dehydrogenase (ELFV_dehydrog), Domain containing 5 cysteine conserved residues (GCC2_GCC3), Metal dependent phosphohydrolases with conserved ‘HD’ motif (HDc), Membrane-attack complex /perforin domain family (MACPF), Phosphoenolpyruvate carboxykinase (PEPCK_ATP), Papain family cysteine protease (Pept_C1), Sexual stage antigen s48/45 domain (s48-45), Thrombospondin type 1 (TSP1), Triose-phosphate Transporter family (TPT), UAA transporter family (UAA), Von Willibrand factor type A domain (VWA).
Orthology predicition from OrthoMCL database (http://www.orthomcl.org) shows OrthoMCL group, nr species Plasm (the number of Plasmodium species, additional nr species Api (number of additional Apicomplexan species without Plasmodium species), additional species other (number of species without Apicomplexan species (including Plasmodium)).
OOC – oocysts; ODS - oocyst-derived sporozoites; SGS - salivary gland sporozoites. The mosquito fraction (mosq fr.) of a protein is calculated by the number of detected peptides in mosquito stages divided by the sum of the number of peptides in mosquito and blood stages.
Genes selected for further functional analysis of their encoded proteins through targeted disruption of their orthologs in the P. berghei rodent model.
|
| Group (1) |
| Exp nr (mutant) (2) | Successful disruption (3) | Oocyst no. mean (s.d.) (2–4 exp) (4) | spor. no. mean (s.d.) (2–3 exp) (5) | spor. infectivity to mice (mosquito bite) (6) | Phenotype (7) | Remarks (8) |
| Control (WT) | - | - | - | 169 (39) | 104000 (14500) | 4 (n = 4) | wild type | - | |
| PF11_0528 | I | PB001073.00.0/PB000529.02.0/PB000863.00.0 | 800, 836 | Yes (2×) | 160 (48) | 64800 (12500) | 2 (n = 2) | Wild type | Redundant function? |
| PF14_0435 | I | PB101363.00.0/PB000829.02.0/PB105739.00.0 | 802, 838 | Yes (2×) | 181 (60) | 0 | 0 (n = 4) | Complete block of sporozoite development inside oocyst | |
| Pf14_0607 | I | PB000015.03.0 | 803, 829, 839 | No (3×) | - | - | - | - | Essential for blood stage? |
| PF14_0074 | II | PB000372.00.0 | 807, 842 | Yes (2×) | 153 (27) | 80200 (16000) | 2 (n = 2) | Wild type | Redundant function? |
| PFF1195c | II | PB107027.00.0/PB107193.00.0/PB001101.03.0 | 801, 837 | Yes (2×) | 165 (47) | 97300 (12200) | 2 (n = 2) | Wild type | Redundant function? |
| PFD0425w | III | PB000251.01.0 | 806, 841 | Yes (2×) | 154 (59) | 375 (125) | 0 (n = 4) | Arrest of sporozoite egress from oocyst | Oocyst sporozoites are infective to mice |
| PFA0205w | III | PB301531.00.0 | 809, 830, 844 | No (3×) | - | - | - | - | Essential for blood stage? |
| MAL8P1.66 | III | PB402680.00.0 | 808, 843 | Yes (2×) | 188 (51) | 2625 (415) | 0 (n = 4) | (Partial) block of sporozoite development inside oocyst | Few sporozoites formed; not infective to mice |
Classification of proteins based on their protein expression patterns. Group I ODS-enriched, group II SGS-enriched, and group III ODS/SGS-enriched.
The experiment numbers ( = mutant number) of 2–3 independent transfection experiments.
Successful disruption was determined by Southern analysis of separated chromosomes and diagnostic PCR of selected, pyrimethamine resistant parasites as shown in Figure S3 and Table S5.
Mean number of oocysts per mosquito and standard deviation (s.d).
Mean number of salivary gland sporozoites per mosquito and standard deviation (s.d).
Infectivity of sporozoites was tested by infecting mice by mosquito bite. The number of mice that showed blood stage infection comparable to wild type infections is shown.
See Figure 3 for details of the characterization of the 3 mutants with a phenotype different from wild type.
OOC – oocysts; ODS - oocyst-derived sporozoites; SGS - salivary gland sporozoites.
Figure 3Phenotypic characterization of P. berghei mutants (841cl1, 843cl1, 802cl1) with disrupted genes.
(A) Numbers of oocyst-derived sporozoites and salivary gland sporozoites per mosquito from day 14 till day 27 post mosquito infection. Scale bars in Figure 3a indicate 50 µm. Wild type (WT) sporozoite numbers are shown in blue bars, 841 clone (PB000251.01.0/PFD0425w) gene disruptant sporozoite numbers in purple, 843 clone (PB402680.00.0/MAL8P1.66) gene disruptant sporozoite numbers in yellow, and 802 clone (PB101363.00.0-PB000829.02.0-PB105739.00.0/PF14_0435) gene disruptant sporozoite numbers are shown in pale blue. (B) Oocysts and sporozoites of the three mutant lines. Upper panel: GFP-expressing mature oocysts at day 10 after infection. Middle panel: Representative images (phase contrast microscopy) of mature (day 12) oocyst. Sporozoite formation in mutant 841 (PB000251.01.0/PFD0425w) is same as WT whereas in lines 843 (PB402680.00.0/MAL8P1.66) and 802 (PB101363.00.0-PB000829.02.0-PB105739.00.0/PF14_0435) sporozoite development is either affected (i.e. 843) or completely absent (i.e. 802). Lower panel: GFP-expressing sporozoites (released by mechanical rupture of oocysts at day 18–20). Scale bars in Figure 3b indicate 12 um. (C) Hepatocyte traversal and invasion of oocyst derived sporozoites (841, PB000251.01.0/PFD0425w)) and salivary gland sporozoites (843, (PB402680.00.0/MAL8P1.66)) compared to WT sporozoites similarly mechanically liberated from oocyst. Bars represent the average percentage of HepG2 cell traversal and invasion relative to wild type. Scale bars in Figure 3c indicate 12 um.